IL79522A - Fusion proteins,a process for their preparation and their use - Google Patents

Fusion proteins,a process for their preparation and their use

Info

Publication number
IL79522A
IL79522A IL79522A IL7952286A IL79522A IL 79522 A IL79522 A IL 79522A IL 79522 A IL79522 A IL 79522A IL 7952286 A IL7952286 A IL 7952286A IL 79522 A IL79522 A IL 79522A
Authority
IL
Israel
Prior art keywords
sequence
amino acids
genetically codable
genetically
fusion protein
Prior art date
Application number
IL79522A
Other versions
IL79522A0 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IL79522A0 publication Critical patent/IL79522A0/en
Publication of IL79522A publication Critical patent/IL79522A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1. Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A fusion protein of the general formula Met - Xn - D' - Y - Z in which n is zero or 1, X is a sequence of 1 to 12 genetically codable amino acids, D' is a sequence of about 70 amino acids in the region of the sequence of amino acids 23 - 93 of the D-peptide in the trp operon of E. coli, Y denotes a sequence of one or more genetically codable amino acids which permits the following amino acid sequence Z to be cleaved off, and Z is a sequence of genetically codable amino acids. 1. Claims for the Contracting State : AT A process for the preparation of a fusion protein of the general formula (1) Met - Xn - D' - Y - Z in which n is zero or 1, X is a sequence of 1 to 12 genetically codable amino acids, D' is a sequence of about 70 amino acids in the region of the sequence of amino acids 23 - 93 of the D-peptide in the trp operon of E. coli, Y denotes a sequence of one or more genetically codable amino acids which permits the following amino acid sequence Z to be cleaved off, and Z is a sequence of genetically codable amino acids, characterized by expressing a gene structure which codes for these fusion proteins in a host cell, and separating the fusion protein.
IL79522A 1985-07-27 1986-07-25 Fusion proteins,a process for their preparation and their use IL79522A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853526995 DE3526995A1 (en) 1985-07-27 1985-07-27 FUSION PROTEINS, METHOD FOR THEIR PRODUCTION AND THEIR USE

Publications (2)

Publication Number Publication Date
IL79522A0 IL79522A0 (en) 1986-10-31
IL79522A true IL79522A (en) 1991-08-16

Family

ID=6276985

Family Applications (1)

Application Number Title Priority Date Filing Date
IL79522A IL79522A (en) 1985-07-27 1986-07-25 Fusion proteins,a process for their preparation and their use

Country Status (18)

Country Link
EP (1) EP0211299B1 (en)
JP (1) JPH07113040B2 (en)
KR (1) KR950000299B1 (en)
AT (1) ATE50596T1 (en)
AU (1) AU595221B2 (en)
CA (1) CA1336329C (en)
DE (2) DE3526995A1 (en)
DK (1) DK172618B1 (en)
ES (1) ES2000278A6 (en)
FI (1) FI86887C (en)
GR (1) GR861957B (en)
HU (1) HU197356B (en)
IE (1) IE59127B1 (en)
IL (1) IL79522A (en)
NO (1) NO175640C (en)
NZ (1) NZ216967A (en)
PT (1) PT83065B (en)
ZA (1) ZA865556B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738541A1 (en) * 1987-11-13 1989-05-24 Hoechst Ag METHOD FOR INSULATING AND CLEANING HIRUDINE
DE3541856A1 (en) * 1985-11-27 1987-06-04 Hoechst Ag EUKARYOTIC FUSION PROTEINS, THEIR PRODUCTION AND USE, AND MEANS FOR CARRYING OUT THE PROCESS
ATE80913T1 (en) * 1986-03-12 1992-10-15 Int Minerals & Chem Corp HYBRID EXPRESSION VECTORS, THEIR PRODUCTION AND USES.
WO1988010299A1 (en) * 1987-06-24 1988-12-29 Novo-Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
GR1005153B (en) * 1989-08-29 2006-03-13 The General Hospital Corporation Fusion proteins their preparation and use
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (en) * 1989-12-22 1991-06-27 Basf Ag METHOD FOR PRODUCING HIRUDINE
DK0821006T3 (en) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulin derivatives with increased zinc binding
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
DE19825447A1 (en) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
EP2522728A1 (en) 2007-09-21 2012-11-14 Cadila Healthcare Limited GCSF fusion protein systems suitable for high expression of peptides
LT2349324T (en) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
CN102711804B (en) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 Comprise the pharmaceutical composition of GLP-1 agonist and methionine
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
RU2546520C2 (en) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Application of ave0010 for production of medication for treatment of type 2 diabetes mellitus
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
HUE062573T2 (en) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR68404B (en) * 1979-06-01 1981-12-29 Univ California
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
AU596585B2 (en) * 1985-03-18 1990-05-10 Genelabs Incorporated Hybrid genes (eg. ig's & mhc proteins) via lambda library andplasmid casette vector
GB8507666D0 (en) * 1985-03-25 1985-05-01 Wellcome Found Epidermal growth factor production
CA1341384C (en) * 1985-04-08 2002-08-20 Susan Mitsue Watanabe Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav

Also Published As

Publication number Publication date
PT83065A (en) 1986-08-01
FI863041A0 (en) 1986-07-24
KR950000299B1 (en) 1995-01-13
EP0211299B1 (en) 1990-02-28
DK172618B1 (en) 1999-03-01
NO175640B (en) 1994-08-01
GR861957B (en) 1986-11-25
JPS6229600A (en) 1987-02-07
ZA865556B (en) 1987-03-25
FI86887C (en) 1992-10-26
AU595221B2 (en) 1990-03-29
DE3669175D1 (en) 1990-04-05
ATE50596T1 (en) 1990-03-15
DK355486D0 (en) 1986-07-25
IL79522A0 (en) 1986-10-31
NO175640C (en) 1994-11-09
DE3526995A1 (en) 1987-02-05
HUT43629A (en) 1987-11-30
PT83065B (en) 1989-02-28
EP0211299A2 (en) 1987-02-25
FI863041A (en) 1987-01-28
AU6056586A (en) 1987-01-29
IE59127B1 (en) 1994-01-12
NZ216967A (en) 1988-08-30
IE861977L (en) 1987-01-27
JPH07113040B2 (en) 1995-12-06
ES2000278A6 (en) 1988-02-01
FI86887B (en) 1992-07-15
DK355486A (en) 1987-01-28
KR870001312A (en) 1987-03-13
NO863000L (en) 1987-01-28
NO863000D0 (en) 1986-07-25
CA1336329C (en) 1995-07-18
EP0211299A3 (en) 1988-06-01
HU197356B (en) 1989-03-28

Similar Documents

Publication Publication Date Title
AU595221B2 (en) Fusion proteins, a process for their preparation and their use
EP0722461A4 (en) Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
YU233582A (en) Process for the expression of a gene coded for human imunological interferon
FI853056L (en) Process for the preparation of polypeptide with hirudin activity
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
ES8603574A1 (en) Production of polypeptides with a human gamma-interferon activity.
PH30889A (en) Dna encoding equuine-gamma interferon and recombination production of equine ifn-polypeptides.
FI880017A0 (en) Method for preparing pancreatic trypsin inhibitor variants and DNA, vector and host cell used in the method
AU9026691A (en) New human recombinant gamma interferon
EP0330700A4 (en) Human prourokinase-like polypeptide.
EP0222279A3 (en) Production of active proteins containing cystine residues

Legal Events

Date Code Title Description
FF Patent granted
RH Patent void